Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B

Creative Commons License

Atay K., Hatemi I., Canbakan B., Koroglu E. , Durcan E. , Yurttas B., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.27, ss.279-283, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 27 Konu: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5152/tjg.2016.16085
  • Sayfa Sayıları: ss.279-283


Background/Aims: Several guidelines recommend the use of tenofovir or entecavir as the first-line treatment for hepatitis B due to the lower resistance rates of these drugs than lamivudine, although lamivudine may still be preferred because of its low adverse effect profile and cost. It is important to know which patients might benefit from lamivudine as the first-line treatment. We aimed to assess the success rates of lamivudine, entecavir, and tenofovir, as well as the resistance rates, frequencies of HBsAg clearance, and risk factors for lamivudine resistance.